However, a phase 1 study of the intravenous EZH2 inhibitor GSK2816126 showed disappointing results in terms of antitumor activity, with only a partial response lasting 3 cycles in 1 patient with DLBCL, for which EZH2 mutation status was unknown [20]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.